Background. Synthetic
human chorionic gonadotropin (hCG)-related
oligopeptides are potent inhibitors of pathogenic inflammatory responses induced by in vivo
lipopolysaccharide exposure or
hemorrhagic shock-induced injury. In this study, we tested whether hCG-related
oligopeptide treatment similarly altered inflammatory responses and innate host defenses in mice during experimental Listeria monocytogenes
infection. Methods. Mice were infected with L. monocytogenes and treated with hCG-related
oligopeptides (LQGV, VLPALP, or AQGV) or
phosphate-buffered saline. Subsequently, mice were analyzed for bacterial loads,
cytokine and
chemokine responses, and inflammatory cell infiltrates in target organs. Results.
Oligopeptide administration increased bacterial numbers in the spleen and liver at 6 h after
infection. Simultaneously, CXCL1/KC and CCL2/MCP-1 plasma levels as well as neutrophil numbers in the spleen, blood, and peritoneal cavity decreased. In contrast, at 18 h after
infection, systemic
tumor necrosis factor alpha,
interleukin 12 p70,
interleukin 6, and
interferon gamma levels increased statistically significantly in
oligopeptide-treated mice compared with controls, which correlated with increased bacterial numbers. Conclusion. These data show that treatment with hCG-related
oligopeptides (LQGV, VLPALP, and AQGV) inhibits early innate immune activation by reducing initial
chemokine secretion following
infection. This leads to bacterial overgrowth with subsequent enhanced systemic
inflammation. Our data underscore the importance of early innate immune activation and suggest a role for hCG-derived
oligopeptides at the placenta that increases the risk of L. monocytogenes
infections.